B
NUVB icon

Bailard’s Nuvation Bio NUVB Stock Holding History

Bailard’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Buy
+27,000
New +$150K ﹤0.01% 720
2021
Q4 		– Sell
-29,100
Closed -$289K – 764
2021
Q3 		$289K Hold
29,100
– – 0.01% 541
2021
Q2 		$271K Buy
+29,100
New +$332K 0.01% 574

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bailard's NUVB Position: Q1 2026 in Review

Bailard opened a new position in Nuvation Bio (NUVB) in Q1 2026: 27,000 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #720 among its holdings. This is a return to the name: Bailard previously reported a position in NUVB as recently as Q3 2021.

Bailard first reported a position in NUVB in Q2 2021 and has held it in 3 quarters since. The position peaked at $289K in Q3 2021. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Bailard held 27,000 shares of Nuvation Bio worth $116K as of Q1 2026.
  • Nuvation Bio was a new Bailard position in Q1 2026.
  • Nuvation Bio made up ﹤0.01% of Bailard's portfolio in Q1 2026, its #720 holding.
  • Bailard first reported a position in Nuvation Bio in Q2 2021 and has held it in 3 quarters since.
  • Bailard's Nuvation Bio position peaked at $289K in Q3 2021.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.